 | Up a level |
Codilupi, Tamara; Szybinski, Jakub; Arunasalam, Stefanie; Jungius, Sarah; Dunbar, Andrew C; Stivala, Simona; Brkic, Sime; Albrecht, Camille; Vokalova, Lenka; Yang, Julie L; Buczak, Katarzyna; Ghosh, Nilabh; Passweg, Jakob R; Rovo, Alicia; Angelillo-Scherrer, Anne; Pankov, Dmitry; Dirnhofer, Stephan; Levine, Ross L; Koche, Richard and Meyer, Sara C (2024). Development of resistance to type II JAK2 inhibitors in MPN depends on AXL kinase and is targetable. Clinical cancer research, 30(3), pp. 586-599. American Association for Cancer Research 10.1158/1078-0432.CCR-23-0163
Stivala, Simona; Codilupi, Tamara; Brkic, Sime; Baerenwaldt, Anne; Ghosh, Nilabh; Hao-Shen, Hui; Dirnhofer, Stephan; Dettmer, Matthias S.; Simillion, Cedric; Kaufmann, Beat A; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S; Passweg, Jakob R; Radimerski, Thomas; Skoda, Radek C; Levine, Ross L and Meyer, Sara C (2019). Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. The journal of clinical investigation, 129(4), pp. 1596-1611. American Society for Clinical Investigation 10.1172/JCI98785
Meyer, Sara C; Ghosh, Nilabh; Stivala, Simona; Baerenwaldt, Anne; Hao-Shen, Hui; Dirnhofer, Stefan; Dettmer, Matthias; Simillion, Cédric; Chiu, Sophia; Keller, Matthew; Kleppe, Maria; Hilpert, Morgane; Buser, Andreas S.; Passweg, Jakob R.; Radimersk, Thomas; Skoda, Radek C.; Levine, Ross L. (2017). Targeting Cell Non-Autonomous MAPK Activation As a Novel Therapeutic Strategy in Myeloproliferative Neoplasms. Blood, 130(Suppl. 1), p. 381. American Society of Hematology
